We value your privacy. We use cookies to improve your browsing experience, show you personalized ads or content and analyze our traffic. By clicking "Accept all" you consent to our use of cookies. You can modify your permissions in "settings".
BRUCELLOSIS
OCUREV
An essential and innovative vaccine to control ovine and caprine brucellosis.
VACCINE OF CHOICE
Manufactured in compliance with OIE and EU standards, OCUREV was the first REV-1 conjunctival vaccine developed and made available. Now, it is an essential tool to control ovine and caprine brucellosis in numerous countries worldwide.
FIRST STEP IN THE CONTROL OF BRUCELLA MELITENSIS
Caprine and ovine brucellosis is a major cause of miscarriage, resulting in significant economic losses for farmers. Vaccination is a practical and effective method to reduce the incidence of brucellosis in endemic areas.
EASY OCULAR ADMINISTRATION
The Patent Blue V makes it easy to differentiate between vaccinated and non-vaccinated animals.
PERFECT DOSE PRECISION
OCUREV combines perfect dissolution of the freeze-dried cake and high dosage precision of the dropper for optimal and efficient ocular application.
LONG-LASTING PROTECTION
OCUREV offers long-lasting protection due to cell-mediated immune response, which is the principal defense mechanism against brucella disease.
Helping decrease human brucellosis
Brucellosis is highly pathogenic for humans, causing one of the most serious zoonoses in the world. Animal vaccination has been shown to reduce the zoonotic spread of the disease, leading to a notable decrease in the prevalence of human brucellosis.
PREVENTING INTERFERENCE WITH SEROLOGICAL TESTS
When OCUREV is administered via ocular route in sheep and goats aged 3 to 6 months, it induces a short-lasting serological response that avoids interference with conventional serological tests. This vaccine is compatible with eradication programs based on mass vaccination and test and slaughter principles.
SUPPRESSION OF THE INFECTION PRESSURE
Vaccination results in elimination of the clinical signs (miscarriages) and the excretion of Brucella melitensis bacteria, thus reducing contamination of the environment and the spread of the disease.
STABILITY
This vaccine against brucellose is extremely stable and shows no tendency to revert virulence. OCUREV has a shelf life of 24 months, allowing prolonged storage with the same quality of protection. Investigations carried out on this vaccine indicate that it is thermostable. It can be transported and kept at a maximum of 37°C for a period not exceeding 7 days, facilitating transport for application in herds that are difficult to access.